OVERVIEW

Virginia Association of Hematologists and Oncologists (VAHO) Virtual Spring Conference 2021 is organized by Virginia Association of Hematologists and Oncologists (VAHO) and will be held on May 21, 2021.

Target Audience:
The target audience for this initiative includes medical oncologists, urologic oncologists, urologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with prostate cancer.

Accreditation Statement:
IPCE credit:
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation for Physicians
AXIS Medical Education designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit JA4008106-9999-21-021-L01-P.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Overview:
The VAHO Spring Conference offers limitless opportunities for strengthening cancer care in Virginia, the latest trends in the cancer treatment pipeline, and fresh perspectives for adjusting to the challenges and changes of healthcare policy on care delivery in our state.

Prostate cancer is the second most common cancer, after skin cancer, among men. It is the second leading cause of cancer death in the United States. This year, it is estimated that about 174,650 men in the United States will be diagnosed with prostate cancer and 31,620 men will die from this disease. Androgen deprivation therapy (ADT) aimed at lowering the level of androgens, is the standard of care for men with advanced prostate cancer. Newly diagnosed metastatic disease that has spread to other parts of the body and still responds to testosterone suppression therapy is called metastatic castration-sensitive prostate cancer (mCSPC). Androgen receptor inhibitors are currently being investigated in combination with ADT given the knowledge that deeper androgen signal inhibition results in further improved outcomes in mCSPC. With the recent drug approvals and updates to clinical practice guidelines, several knowledge, competence and performance gaps exist in the optimal management of mCSPC among oncology practitioners. Participants from previous Association of Community Cancer Centers (ACCC) educational programs revealed transitions of care, including communication between the numerous healthcare settings (52%), side effect management (45%), and keeping current on the latest treatment modalities (29%) as among the most commonly encountered challenges for practitioners.

This education activity will provide guidance on the optimal management of mCSPC to oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The educational program will address some of the challenges in optimal sequencing of care in mCSPC and will provide an opportunity to discuss with leading oncology experts and colleagues how new research clinical updates can be translated into new patient care strategies.

Topics include - but are not limited to - the following:
• Emerging Therapies for the Management of Castration-Sensitive Prostate Cancer*
• Oncology Care Model/Oncology First Model
• Advanced Practice Providers: Productivity and Value

Learning Objectives:
At the end of this educational activity, participants should be able to:
• Describe current and emerging treatment options in mCSPC.
• Employ strategies for optimal management of treatment-related adverse events experienced by patients treated for mCSPC.
• Examine solutions for improving coordination and communication within the multidisciplinary cancer care team and with patients/caregivers to improve outcomes for patients with mCSPC.